ArticleExperimental hematology & oncology2026
Defining the cellular and molecular identities of histologic subtypes in lung adenocarcinoma.
Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A radiotherapy-related fibrosis gene signature-based risk model for predicting prognosis and immunological features in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Characterization of telomere-related gene subtypes in lung adenocarcinoma and their implications for prognosis and treatment.Discover oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundTumor histology reflects disease aggressiveness and clinical outcomes in cancer patients. Lung adenocarcinomas (LUADs) are classified based on predominant histologic patterns, including high-grade micropapillary and solid subtypes which portend unfavorable clinical features and prognosis. However, the cellular and molecular characteristics underlying these histologic subtypes remain largely unknown.
methodsWe used scRNA-seq to profile 117,266 cells from 18 treatment-naïve LUADs with heterogeneous histologic patterns and also performed spatial transcriptomic analysis (10x Visium) for representative cases. By integrating single-cell transcriptomics with spatial information, we aimed to characterize the cellular identity and spatial organization driving LUAD heterogeneity.
resultsWe demonstrated that histologic subtypes can be distinguished by subtype-specific cancer cell subpopulations and immunosuppressive phenotypes in the tumor microenvironment (TME). Our data reveal how intercellular interactions among cancer cells, macrophages, and CD8
conclusionsThese findings deepen our understanding of the histologic heterogeneity of LUAD and may facilitate the development of subtype-specific biomarkers and targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.